Home / Stocks / BMXMF

bioMérieux S.A. (BMXMF, Medical devices) Stock Valuation & Fair Value

Poor on forward returns

bioMérieux S.A. (BMXMF, Medical devices) trades at a current P/E of 20.5, about 18% below its historical normal valuation, with a forward growth estimate of 6.1% and a PEG of 3.37. Analysts' one-year estimates have been hit 55% of the time. Priced at its historical normal P/E of 24.9 on the same blended earnings, the 2026-11-06 close of $103.48 corresponds to about $126 a share. This is a valuation reference, not a price target. The $103.48 close is the one the P/E is read at; the technical context below uses the 2026-11-05 close, $102.14.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-07
Current P/E
20.5
Normal P/E
24.9
PEG
3.37
Fwd growth
6.1%
Div yield
1.1%
RSI (14)
84.1
Overbought
Technical context
  • Price $102.14 at the Nov 5 close, 3.1% above the 20-day average ($99.08) and 12.2% above the 50-day ($91.00).
  • RSI (14) at 84.1.
  • 52-week range $76.34 to $130.27: the price is 21.6% below the high and 33.8% above the low.

Valuation flags

Verdict history

tickerseer's rating moved from mixed on our tests (2026-09-19) to weak on forward returns (2026-11-02).

Current P/E and rating by weekCurrent P/E moved from 16.1 to 20.2 between 2026-09-18 and 2026-10-30, against a normal P/E of 24.9, with 1 rating change over 7 recorded weeks.2026-09-18: P/E 16.1, Mixed on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 16.1, Mixed on our tests, recorded live 2026-09-212026-09-25: P/E 17.3, Mixed on our tests, recalculated for the week of 2026-09-262026-09-25: P/E 17.3, Mixed on our tests, recorded live 2026-09-282026-10-02: P/E 16.8, Mixed on our tests, recalculated for the week of 2026-10-032026-10-02: P/E 16.8, Mixed on our tests, recorded live 2026-10-052026-10-09: P/E 18.0, Weak on forward returns, recalculated for the week of 2026-10-102026-10-09: P/E 18.0, Weak on forward returns, recorded live 2026-10-122026-10-16: P/E 19.4, Weak on forward returns, recalculated for the week of 2026-10-172026-10-16: P/E 19.4, Weak on forward returns, recorded live 2026-10-192026-10-23: P/E 19.6, Weak on forward returns, recalculated for the week of 2026-10-242026-10-23: P/E 19.6, Weak on forward returns, recorded live 2026-10-262026-10-30: P/E 20.2, Weak on forward returns, recalculated for the week of 2026-10-312026-10-30: P/E 20.2, Weak on forward returns, recorded live 2026-11-0217.520.022.5Sep 18Sep 28Oct 9Oct 20Oct 30Normal P/E 24.9
Mixed on our testsWeak on forward returns

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 16.1-35%Mixed on our tests (recalculated)
2026-10-10P/E 18.0-28%Weak on forward returns (recalculated)
2026-10-31P/E 20.2-19%Weak on forward returns (recalculated)
2026-11-02P/E 20.2-19%Weak on forward returns ← now
Show all 14 readings
WeekCurrent P/EPremium to normal P/ERating
2026-09-19P/E 16.1-35%Mixed on our tests (recalculated)
2026-09-21P/E 16.1-35%Mixed on our tests
2026-09-26P/E 17.3-31%Mixed on our tests (recalculated)
2026-09-28P/E 17.3-31%Mixed on our tests
2026-10-03P/E 16.8-33%Mixed on our tests (recalculated)
2026-10-05P/E 16.8-33%Mixed on our tests
2026-10-10P/E 18.0-28%Weak on forward returns (recalculated)
2026-10-12P/E 18.0-28%Weak on forward returns
2026-10-17P/E 19.4-22%Weak on forward returns (recalculated)
2026-10-19P/E 19.4-22%Weak on forward returns
2026-10-24P/E 19.6-21%Weak on forward returns (recalculated)
2026-10-26P/E 19.6-21%Weak on forward returns
2026-10-31P/E 20.2-19%Weak on forward returns (recalculated)
2026-11-02P/E 20.2-19%Weak on forward returns ← now

Frequently asked questions

Is bioMérieux S.A. stock overvalued?

At a current P/E of 20.5 versus its historical normal P/E of 24.9, bioMérieux S.A. trades about 18% below its typical valuation, with a PEG of 3.37 on 6.1% forward growth. tickerseer currently rates it poor on forward returns.

What is bioMérieux S.A.'s fair value and PEG?

bioMérieux S.A. trades at a current P/E of 20.5 against a historical normal P/E of 24.9, a PEG of 3.37, and a forward growth estimate of 6.1%. Priced at its historical normal P/E of 24.9 on the same blended earnings, the 2026-11-06 close of $103.48 corresponds to about $126 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of bioMérieux S.A. changed?

tickerseer's rating moved from mixed on our tests (2026-09-19) to weak on forward returns (2026-11-02).

Industry: Medical devices. Create a free account to see the full analysis: the SeerAI score, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track BMXMF free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.